A new study suggests the shingles vaccine could reduce dementia risk and may even slow progression in those already diagnosed, offering hope for millions.
The UK-US pharma deal removes tariffs, boosts NHS access to innovative medicines, and drives significant life-sciences investment, safeguarding patients and industry growth.
GSK is investing £45 m with the Fleming Initiative to launch six “Grand Challenge” research programmes using cutting-edge AI to tackle antimicrobial resistance against pathogens like MRSA, Gram-negative bacteria, and fungi.
The UK’s Horizon trial will test a vaccine against the Epstein-Barr virus (EBV), linked to multiple sclerosis, aiming to train the immune system and explore a potential new treatment for MS.
NHS hospitals are piloting a rapid 15-minute blood test to distinguish viral vs bacterial infections in children, enabling faster diagnosis and treatment of serious illnesses like sepsis and meningitis.
Researchers at the University of Surrey are creating immune digital twins, virtual models of individual immune systems, to advance personalised medicine and deliver tailored treatments.
University of Liverpool researchers receive £2.4 million to advance a minimally invasive treatment for keratoconus, aiming to improve patient access and reduce NHS costs.
A new systematic review shows that nasal spray adrenaline (via liquid or powder sprays) can be as fast or faster than injections for treating anaphylaxis, a possible needle-free alternative to EpiPen®.
Rising costs, unpredictable policies, and dwindling incentives are forcing Big Pharma to rethink the UK, with leading firms pausing multi-million-pound R&D projects, but why is the country losing its competitive edge?
A new study reveals that daily use of eye drops, which combine pilocarpine and diclofenac, can significantly enhance near vision for presbyopia patients.
